Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene ...

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

Kirkland & Ellis lawyers withdrew from representing Novartis AG in a lawsuit against Regeneron Inc. a week after the firm was ...

Through this program, Regeneron has committed to matching donations at a one-to-one rate, up to a total of $200 million, for ...

This was the stock's second consecutive day of gains.

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...